BOSTON--(BUSINESS WIRE)--XenoTherapeutics, a life science company developing the first non-human organ transplant solution currently under investigational review by the FDA, announced that company co-founders Paul Holzer, CEO and Jon Adkins, COO presented an update on the company’s pre-clinical progress for its skin transplant solution at the 2018 Dan Morton Meeting of the Boston Area Pharmaceutical Toxicology Group. The conference, held today at the Novartis Institutes for BioMedical Research in Cambridge, hosted representatives from a variety of biotechnology companies on the cutting-edge of research and development.
XenoTherapeutics’ first non-human organ transplant solution, Xeno-Skin™, has been submitted to the FDA via IND for use as an investigational drug. The company is in active preparations to enroll patients in this first-in-man clinical study.
“Xeno-Skin is on the verge of becoming the first non-human organ transplant approved by the FDA for investigational use,” said Paul Holzer, CEO and Co-founder of XenoTherapeutics. “Our goal with this initial product is to advance the science of xenotransplantation for practical therapies that can benefit patients around the globe, while also addressing a critically unmet need for burns and other severe skin wounds.”
Xeno-Skin is intended to serve as a replacement or a complement to human cadaver allograft, the current standard of care for burn treatment. However, unlike the limited quantity of lifesaving human graft material available, Xeno-Skin is intended to be mass-produced, stored, and rapidly shipped when needed. Ultimately, the goal is to increase emergency preparedness for unexpected catastrophic events and fill current shortages experienced far too frequently around the world today. XenoTherapeutics’ pipeline starts with skin transplantation, but envisions myriad other applications of the technology, including nerves and solid organs.
XenoTherapeutics’ mission is to solve one of the greatest challenges to modern medicine today: the global shortage of organs and tissues for transplants. The company has developed a first non-human organ transplant solution currently under investigational review by the FDA, which has the potential to advance the science of xenotransplantation and help address the critically unmet need for organs and tissues for patients around the globe.
For more information, please visit: https://www.xenotherapeutics.org/